Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674990 | 0.86 | USP2 (0.38) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL28983304 | 0.85 | USP2 (0.42) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL16506171 | 0.85 | USP2 (0.42) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL2525863 | 0.82 | GSR (0.39) | USP2SLCO1B1PDE4ADPP4DPP8 | |
| SCHEMBL1127060 | 0.81 | ALOX15 (0.41) | ALOX15BLMPMP22KMT2AUSP2 | |
| SCHEMBL5054613 | 0.81 | USP2 (0.35) | USP2SLCO1B1PDE4A | |
| SCHEMBL736616 | 0.81 | USP2 (0.39) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL14659366 | 0.81 | USP2 (0.34) | USP2SLCO1B1PDE4A | |
| SCHEMBL3787584 | 0.81 | USP2 (0.39) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL15145985 | 0.80 | USP2 (0.41) | USP2SLCO1B1PDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916950-A | Compositions comprising Sbi adjuvants and methods of use thereof | 螺旋纳米技术公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11692184-B2 | Thermostable RNA-guided endonucleases and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | disclosed |
| CN-215799636-U | Perfusion culture device for suspension cell ventilation bag | 比欧联科供应链管理(北京)有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210324321-A9 | CROSS-SCALE MODELING OF BIOREACTOR CULTURES USING RAMAN SPECTROSCOPY | BIOGEN MA INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-11118194-B2 | Modified site-directed modifying polypeptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200392447-A1 | CROSS-SCALE MODELING OF BIOREACTOR CULTURES USING RAMAN SPECTROSCOPY | BIOGEN MA INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200392472-A1 | THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2020-12-17 | — | — | US | disclosed |
| US-10563163-B2 | Cross-scale modeling of bioreactor cultures using Raman spectroscopy | BIOGEN MA INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2019103984-A1 | COMPOSITIONS INCLUDING FATP1, FATP3, FATP4, FATP5, AND/OR FATP6 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-05-31 | — | — | WO | disclosed |
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | ZADEC APS (DK) | 2019-01-08 | — | — | US | disclosed |
| WO-1999007701-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | SUGEN, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5827729-A | BLOOD DIALYSIS USING CULTURED LIVER TISSUE TO CLEANSE BLOOD WHICH FLOWS OVER ONE SIDE OF THE TISSUE WHILE NUTRIENTS FLOW OVER THE OTHER; DIFFUSION OF WASTES | ADVANCED TISSUE SCIENCES (US) | 1998-10-27 | — | — | US | disclosed |
| EP-0812210-A4 | COMPOSITIONS AND METHODS FOR ENHANCING THE GROWTH OF HAIR AND RESTORING HAIR COLOR | LIFE MEDICAL SCIENCES INC (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0812210-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE GROWTH OF HAIR AND RESTORING HAIR COLOR | LIFE MEDICAL SCIENCES, INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1997039624-A1 | DIFFUSION GRADIENT BIOREACTOR AND EXTRACORPOREAL LIVER DEVICE | ADVANCED TISSUE SCIENCES, INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1996025943-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE GROWTH OF HAIR AND RESTORING HAIR COLOR | LIFE MEDICAL SCIENCES, INC. (US) | 1996-08-29 | — | — | WO | disclosed |
| EP-0306607-A1 | Vaccines for gram-negative bacteria | MILES INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| US-4693891-A | NONTOXIC, COUPLED PROTEIN, POLYSACCHARIDE AND LIPOPOLYSACCHARIDE | MILES LABORATORIES, INC. (US) | 1987-09-15 | — | — | US | disclosed |
| EP-0118831-A2 | Vaccines for gram-negative bacteria and method for the preparation thereof | MILES INC. (US) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174065-B2 | Antidiabetic enolic glucoside of phenylpyruvic acid | PC, SLC5A1, SLC5A2 | ALOX15 1819/4885BLM 4746/4885PMP22 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.